Strategies for the development of new PPAR agonists in diabetes

Matthew A. Cavender, Stephen J. Nicholls, A. Michael Lincoff

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Diabetes is associated with a range of metabolic abnormalities including insulin resistance, atherogenic dyslipidemia, hypertension, and inflammation. These factors are likely to underlie the adverse cardiovascular outcome typically observed in diabetic cohorts. The family of peroxisome proliferator-activated receptors (PPARs) have been implicated in the regulation of a number of physiologic and metabolic pathways. Pharmacologic agonists directed against various PPARs have been shown to have a beneficial impact on these metabolic risk factors. The potential impact on cardiovascular risk with the use of PPAR agonists will be reviewed.

LanguageEnglish
JournalEuropean Journal of Cardiovascular Prevention and Rehabilitation
Volume17
Issue numberSUPPL. 1
DOIs
Publication statusPublished - May 2010
Externally publishedYes

Keywords

  • Coronary artery disease
  • Diabetes
  • Peroxisome proliferator- activated receptors
  • Prevention

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Epidemiology

Cite this

Cavender, Matthew A. ; Nicholls, Stephen J. ; Lincoff, A. Michael. / Strategies for the development of new PPAR agonists in diabetes. In: European Journal of Cardiovascular Prevention and Rehabilitation. 2010 ; Vol. 17, No. SUPPL. 1.
@article{9b39b1a1df95447d9cbe1eaa3a4974e3,
title = "Strategies for the development of new PPAR agonists in diabetes",
abstract = "Diabetes is associated with a range of metabolic abnormalities including insulin resistance, atherogenic dyslipidemia, hypertension, and inflammation. These factors are likely to underlie the adverse cardiovascular outcome typically observed in diabetic cohorts. The family of peroxisome proliferator-activated receptors (PPARs) have been implicated in the regulation of a number of physiologic and metabolic pathways. Pharmacologic agonists directed against various PPARs have been shown to have a beneficial impact on these metabolic risk factors. The potential impact on cardiovascular risk with the use of PPAR agonists will be reviewed.",
keywords = "Coronary artery disease, Diabetes, Peroxisome proliferator- activated receptors, Prevention",
author = "Cavender, {Matthew A.} and Nicholls, {Stephen J.} and Lincoff, {A. Michael}",
year = "2010",
month = "5",
doi = "10.1097/01.hjr.0000368196.17109.5e",
language = "English",
volume = "17",
journal = "European Journal of Cardiovascular Prevention and Rehabilitation",
issn = "1741-8267",
publisher = "SAGE Publications Inc.",
number = "SUPPL. 1",

}

Strategies for the development of new PPAR agonists in diabetes. / Cavender, Matthew A.; Nicholls, Stephen J.; Lincoff, A. Michael.

In: European Journal of Cardiovascular Prevention and Rehabilitation, Vol. 17, No. SUPPL. 1, 05.2010.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Strategies for the development of new PPAR agonists in diabetes

AU - Cavender, Matthew A.

AU - Nicholls, Stephen J.

AU - Lincoff, A. Michael

PY - 2010/5

Y1 - 2010/5

N2 - Diabetes is associated with a range of metabolic abnormalities including insulin resistance, atherogenic dyslipidemia, hypertension, and inflammation. These factors are likely to underlie the adverse cardiovascular outcome typically observed in diabetic cohorts. The family of peroxisome proliferator-activated receptors (PPARs) have been implicated in the regulation of a number of physiologic and metabolic pathways. Pharmacologic agonists directed against various PPARs have been shown to have a beneficial impact on these metabolic risk factors. The potential impact on cardiovascular risk with the use of PPAR agonists will be reviewed.

AB - Diabetes is associated with a range of metabolic abnormalities including insulin resistance, atherogenic dyslipidemia, hypertension, and inflammation. These factors are likely to underlie the adverse cardiovascular outcome typically observed in diabetic cohorts. The family of peroxisome proliferator-activated receptors (PPARs) have been implicated in the regulation of a number of physiologic and metabolic pathways. Pharmacologic agonists directed against various PPARs have been shown to have a beneficial impact on these metabolic risk factors. The potential impact on cardiovascular risk with the use of PPAR agonists will be reviewed.

KW - Coronary artery disease

KW - Diabetes

KW - Peroxisome proliferator- activated receptors

KW - Prevention

UR - http://www.scopus.com/inward/record.url?scp=77952945832&partnerID=8YFLogxK

U2 - 10.1097/01.hjr.0000368196.17109.5e

DO - 10.1097/01.hjr.0000368196.17109.5e

M3 - Review article

VL - 17

JO - European Journal of Cardiovascular Prevention and Rehabilitation

T2 - European Journal of Cardiovascular Prevention and Rehabilitation

JF - European Journal of Cardiovascular Prevention and Rehabilitation

SN - 1741-8267

IS - SUPPL. 1

ER -